- Home
- ADNT vs PSNL Comparison
ADNT vs PSNL Comparison
Compare ADNT & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADNT | PSNL |
|---|---|---|
| Founded | 2016 | 2011 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2016 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ADNT | PSNL |
|---|---|---|
| Price | $20.77 | $14.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 5 |
| Target Price | ★ $25.41 | $12.20 |
| AVG Volume (30 Days) | 957.3K | ★ 4.0M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.58 |
| EPS | ★ 0.38 | N/A |
| Revenue | ★ $17,439,000,000.00 | $69,648,000.00 |
| Revenue This Year | $2.71 | $15.34 |
| Revenue Next Year | $2.36 | $41.46 |
| P/E Ratio | $52.71 | ★ N/A |
| Revenue Growth | ★ 7.56 | N/A |
| 52 Week Low | $17.68 | $4.44 |
| 52 Week High | $27.32 | $16.39 |
Technical Indicators
Market Signals| Indicator | ADNT | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 57.66 |
| Support Level | N/A | $6.89 |
| Resistance Level | N/A | $16.39 |
| Average True Range (ATR) | 0.00 | 0.59 |
| MACD | 0.00 | 0.09 |
| Stochastic Oscillator | 0.00 | 80.40 |
Price Performance
Historical ComparisonAbout ADNT Adient plc
Adient began trading Oct. 31, 2016, when Johnson Controls spun off its automotive experience segment. Adient is a leading seating supplier to the industry with about a midteens share of the global market including unconsolidated joint venture business. Its share in China is around 20%, down from about 45%, following the sale of its main joint venture there at the end of fiscal 2021. Unconsolidated revenue from joint ventures was about $3.5 billion in fiscal 2025 and consolidated China revenue was $1.3 billion. The company is headquartered in Ireland but has corporate offices in the Detroit area. Fiscal 2025 (Sept. 30 year-end) consolidated revenue, which excludes joint venture sales, was $14.5 billion.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.